Citation Impact

1 by Nobel laureates 62 standout
Sub-graph 1 of 23

Citing Papers

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer
2024 Standout
2 intermediate papers

Works of T.-Y. Kim being referenced

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
2019

Author Peers

Author Oncology PRM Hepatology Last Decade Papers Cites
T.-Y. Kim 203 120 120 19 391
J.F. Caddy 56 3.0k
A Hugelin 3 193 61 1.2k
R.T. Naudé 1 39 637
Daniël Brand 35 1.1k
Patricia Morcillo 15 8 27 841

All Works

Loading papers...

Rankless by CCL
2026